Wichita Falls PD: Woman admitted to having marijuana stashed in her drawers – Times Record News

A Wichita Falls woman is accused of having marijuana stowed in her underwear during a traffic stop Wednesday that led to drug charges against her and a man — who is already on probation for a shoe-related stickup, according to police and court records. 

Officers found pot, methamphetamine and Tetrahydrocannabinol during searches, police said.  

Sienna Jo Hunsaker, 18, was charged with felony possession of 1 to less than 4 grams of methamphetamine and misdemeanor possession of less than two ounces of pot, according to court records.

If convicted of the felony charge, Hunsaker faces up to 10 years in prison.  

Lane Preston Lukash, 19, was charged with possession of 4 to less than 400 grams of THC and possession of 1 to less than 4 grams of meth, both felonies, court documents show. 

THC is a compound in marijuana that produces a feeling of being high. 

If convicted, Lukash faces up to 20 years in prison on the THC charge and 10 years in prison on the meth charge.

Hunsaker was free Thursday from Wichita County Jail on $5,500 in bonds, online jail records show. 

Lukash was free Thursday from Wichita County Jail on $15,000 in bonds, according to online jail records. 

He has been serving an eight-year term of probation for aggravated robbery since Sept. 13. Aggravated robbery is punishable by up to life in prison. 

Lukash had a business selling shoes, but when he met another kid to buy his shoes on Sept. 17, 2018, an accomplice pulled a gun, according to an affidavit for arrest warrant. Then Lukash and the accomplish took the kid’s shoes and left. 

A warrant was issued for Lukash’s arrest May 12 for suspected probation violation. A pre-trial conference on revoking his probation is set for June 26 in 30th District Court.  

Sgt. Charlie Eipper, Wichita Falls police public information officer, provided this account for the recent drug charges from probable cause affidavits:

Officers conducted a traffic stop about 9:03 p.m. Wednesday on a black Dodge Charger at Southwest Parkway and Fairway Boulevard. 

The car, driven by Lukash, had failed to signal 100 feet before the intersection of Mistletoe Drive and Johnson Road. Hunsaker was the front passenger. 

An officer detected the order of marijuana wafting from the Dodge, and she had the occupants get out of the car.

During a search of the car, the officer found what she believed to be pot. 

A brown rolling paper with a green leafy substance inside that smelled like marijuana was in the glove compartment directly in front of Hunsaker. 

Officers continued to search and discovered several pill capsules with a yellow-brown tinted crystallized substance inside them. The capsules were also in the glove box. 

They found several more capsules on the floor next to where Hunsaker was sitting, in between the front passenger door and the front passenger seat. 

An officer questioned the occupants of the vehicle, and other officers observed and asked a few questions.

But none of the occupants admitted to ownership of the narcotics in the car.

Hunsaker admitted she had pot stashed in her underwear, and an officer found a small baggie of a green leafy substance hidden there.  

The leafy substance tested positive for marijuana using a test kit. The crystallized substance in the capsules tested positive for meth.

Searching the vehicle also turned up four THC cartridges still in the box, each labeled as weighing 1 gram, under the driver’s seat. The cartridges tested positive for THC. 

Trish Choate, enterprise watchdog reporter for the Times Record News, covers education, courts, breaking news, politics and more. Contact Trish with news tips at tchoate@gannett.com. Her Twitter handle is @Trishapedia

CBD is a compound found in hemp plants. Here’s what researchers know about its benefits and risks. – Insider – INSIDER

  •  Unlike marijuana, CBD comes from hemp plants bred to have a very low concentration of THC, which means that CBD will not get you high.
  • There’s limited research on the effects of CBD, but some studies have found that it may help reduce pain and benefit patients with schizophrenia, anxiety, and addiction.
  • But CBD can cause side effects like nausea and sleepiness.
  • This article was medically reviewed by Zlatin Ivanov, MD, who is certified in psychiatry and addiction psychiatry by the American Board of Psychiatry and Neurology at Psychiatrist NYC.
  • Visit Insider’s Health Reference library for more advice.

Cannabidiol (CBD) is a compound found in marijuana and hemp plants that has recently skyrocketed in popularity. Companies market it as a remedy for everything from acne to high blood pressure. 

While there are some preliminary studies on how CBD affects the body, more research is needed to understand all its different health benefits. Here’s what researchers know so far about CBD and its effects.

The difference between marijuana and CBD

Marijuana and CBD products both come from cannabis plants. The difference is that marijuana comes from plants that contain a larger amount of the psychoactive substance called Tetrahydrocannabinol (THC). 

Whereas the industrial hemp plants bred for CBD products are required by US law to contain no more than 0.3 percent THC. In other words, „CBD does not get you high,” says Houman Danesh, MD, the director of Integrative Pain Management at Mount Sinai.

Though more research is needed, there is early evidence that CBD can help treat a wide variety of conditions including:


Many pain relief studies have looked at how CBD interacts with THC to help relieve pain, rather than CBD alone. Studies show that a THC-CBD combination can significantly decrease pain for both cancer patients and people with multiple sclerosis.


 CBD has been shown to reduce activity in the areas of your brain that cause worry and fear. This may help explain why preliminary studies indicate that it helps with anxiety and insomnia.

For example, a small 2019 study involving 57 men found that taking 300 milligrams of CBD helped participants feel less anxious while doing a public speaking test. But oddly enough neither higher nor lower doses worked as well.


Early studies suggest that CBD may help people with addiction by decreasing their desire for the addictive substance. A 2013 study found that smokers who took CBD smoked fewer cigarettes during the study period. 

Scientists are also hopeful that CBD can help prevent opioid users from relapsing. A preliminary 2015 study found that people addicted to opiates reported feeling fewer cravings when seeing images or videos of heroin for up to a week after taking CBD.


Early research suggests that CBD may help treat the symptoms of schizophrenia, including hallucinations and delusions. This could be an important finding because traditional medications that treat schizophrenia often have serious side effects like uncontrolled movements and significant weight gain.

Though scientists do not yet understand how CBD works to treat schizophrenia, a 2012 study found that 600 to 800 mg of CBD worked just as well as the standard antipsychotic medication therapy, but with fewer side effects. However,  other studies have found CBD to be less effective.


The only CBD treatment that is approved by the FDA is for rare forms of epilepsy, a potentially life-threatening condition that causes seizures. Though scientists are still not sure exactly how CBD decreases seizures in epilepsy patients, it may help increase the availability of a brain chemical called adenosine, which can help to control seizures.

Though we know that CBD can cause side effects like nausea or sleepiness, we don’t yet know about more serious risks over the long term.

„The risks of CBD itself simply haven’t been studied,” says J.H. Atkinson, MD, co-director of the California Center for Medicinal Cannabis Research.

One risk we are aware of is that CBD seems to interact with certain drugs like blood thinners, increasing how much of the drug stays in your bloodstream, Atkinson says.

The main risk of CBD products, however, is that they are not regulated by the FDA. This means that if you buy a bottle of CBD capsules, it may contain more or less CBD than the label says. „These fluctuations can be as high as 50-100% higher or lower than the stated claims,” Danesh says.

One way to help ensure that you’re getting the proper dose is to get CBD products that are 3rd party tested by an independent lab. For more details, LA Weekly has a list of CBD companies that use third party testing.

CBD comes in many different forms, including edible gummies, vaping oil, tinctures, and skin cream. If you do decide to try CBD, it’s best to stick to methods that don’t involve smoking or vaping, as these can lead to lung issues. The safest way to take CBD is by mouth, Danesh says.

But even when taking CBD by mouth, there are some complications, Atkinson says. When you digest CBD, it can take much longer for the effects to start compared with smoking or vaping, so there is a risk that people may take too much, thinking it isn’t working.

There are currently no studies that show any major health risks from CBD, but for some people, taking high doses can cause side effects like diarrhea or drowsiness. It’s also wise to proceed with caution since more research is needed to ultimately determine CBD’s effectiveness for certain conditions.

And remember, as with any new treatment, it’s best to discuss starting CBD supplements with your doctor first.

Pet Owners Making the Cannabis Connection – Progressive Grocer

„I was skeptical at first, but now I’m a believer,” asserts Allison Williams, a 39-year-old nail technician from Roanoke, Va. After spending months looking for some relief for her elderly cat’s feline arthritis, Williams tried CBD oil on the recommendation of a friend, and couldn’t believe the results. “I’m practically an evangelist now,” she adds. “I’m always telling everyone about it. If you love your pet, give them CBD.”

Key Takeaways

  • Now that the pet product market has embraced CBD in the same way that human wellness brands have, there are many options on retail store shelves.
  • CBD products can help animals with such issues as pain management, internal inflammation and, in particular, anxiety.
  • The target consumers for these products will often be pet owners in search of alternatives to prescription drugs or pricey medical intervention, with product quality a huge factor in sales. 

It’s no secret that humans love their pets. More than half of American homes include a pet, according to the Stamford, Conn.-based American Pet Products Association (APPA). “Our pets are a part of our families, so naturally people treat them as such,” says Vincent Gillen, VP of sales for Tampa, Fla.-based Global Widget LLC, the manufacturer and distributor of Perfect Paws Hemp for pets, Hemp Bombs and Nature’s Script. “Just as we ensure that everything we use on a daily basis is of the best material and uses premium ingredients, we want our pets to have premium-made toys, food, supplements, bedding products and additional pet supplies.”

CBD and Your Pets

Humans have been using CBD oil products for decades to relieve anxiety and depression, reduce inflammation, improve sleep patterns, and combat health conditions like epilepsy. In the past decade, as pro-cannabis attitudes and legislation have swept the United States, CBD products have become highly popular. As humans discovered the health benefits of these products, they also began to wonder whether their pets could benefit as well.

Now that the pet product market has embraced CBD in the same way that human wellness brands have, there are many options on the shelves. “CBD can be used in edible form such as oils, or in a topical form such as paw butter,” notes Gillen. Global Widget’s Perfect Paws Hemp Paw Butter is a topical product that gently repairs dry and cracked paws while adding an extra layer of protection against harsh terrain. Each 2-ounce container contains 250 milligrams of CBD and is prepared with a blend of natural oils such as coconut and sweet almond oil.

„One of the biggest misconceptions about CBD is that it’s marijuana. While the plants are both members of the cannabis family,” explains Gillen, “they differ significantly in composition. Hemp plants have less than 0.3% THC [tetrahydrocannabinol, the principal psychoactive constituent of cannabis]. In contrast, marijuana has anywhere from 3% to 35% THC.”

Pet Owners Making the Cannabis Connection

Actually, CBD — short for cannabidiol — is just one type of cannabinoid that comes from cannabis. Other notable cannabinoids include CBG, CBN and THC.

“All have specific functions in our body,” observes Derek Thomas, VP of business development for Fort Lauderdale, Fla.-based Veritas Farms, a vertically integrated full-spectrum hemp oil product manufacturer and brand. “But it is the combination of them that has the most pronounced effect on us, called the Entourage Effect. Formulations that naturally include all of the cannabinoids found in cannabis [are] called full-spectrum hemp oil and … considered superior to CBD-isolate products.”

When used properly, CBD offers a host of benefits for pets. “It can help animals with pain management, internal inflammation and, most commonly, anxiety,” says Sean McDonald, COO of Corona, Calif.-based CBD Living, one of the fastest-growing global CBD manufacturers and distributors. “We see a lot of customers buying our products for anxious pets.” With more than 100 items in 5,000 stores, and shipping to consumers worldwide, CBD Living offers a wide variety of products, including tablets, sprays and topical solutions.

Pet Owners Making the Cannabis Connection

“A new study in Scientific Reports found that more than 70% of dogs experience anxiety,” continues McDonald. “This can be year-round, but also situational. For example, we find that our sales spike around the holiday season and around holidays that typically involve fireworks. From younger dogs and rescue animals with separation anxiety, to older pets with age-related joint pain and mobility issues, CBD can be helpful through all stages of an animal’s life.”

Stocking Up

When choosing which products to stock on retail shelves, it’s important to choose those that appeal to your customer base. In terms of CBD products, your audience will often be pet owners who want alternatives to prescription drugs or pricey medical intervention. Product quality will be a huge factor in sales. Do your research before you stock the shelves. The most important things to keep in mind when researching brands and products in the pet CBD category are quality, safety and transparency.

Pet CBD products require very specific packaging requirements. Gillen lists the elements of a good label: “Labels should include all the product’s ingredients, both active and additional ingredients; QR codes; batch numbers; expiration dates; and where the product was made. The QR codes and batch numbers are the information that consumers will need to look up full-panel third-party lab results, ensure the compliance and safety of the product for their pets, and read additional CBD education resources.”

Pet Owners Making the Cannabis Connection

Lab testing is especially important because consumers should be able to independently confirm the ingredients of the products. The COA (Certificate of Analysis) should come from an ISO (International Organization for Standardization)-certified lab. Veritas Farms’ Thomas gives more details: “The COA needs to consist of a cannabinoid profile analysis, terpene analysis, pesticide/fungicide/herbicide analysis, heavy-metal analysis and mycotoxin/microbial analysis. There is a key final piece here that many miss — that COA needs to be directly tied to the product via a lot or batch number that is specific to that product and COA.” This allows consumers to cross check the specific information, which is important to the well-informed buyer.

Veritas Farms — which takes its name from the Latin word for “truth” — is known as a trusted brand in this category because of its dedication to transparency. Thomas warns against stocking brands that don’t value transparency as much. “There are many opportunistic brands out there,” he cautions. “If a brand cannot give you complete visibility on their supply chain and cannot provide you with a third-party ISO-certified lab’s analysis that tests for potency and all contaminants and matches to the lot/batch number of the product, then they probably should be avoided.”

More Good Advice

That’s also the case if you’re working with a company that just expanded its product lineup with a CBD product instead of producing a fully developed CBD line from the ground up. CBD Living’s McDonald says that retailers have to be careful about choosing which product to stock.

Pet Owners Making the Cannabis Connection

“Retailers should look for companies that have a history in the market — companies that aren’t just adding CBD products to their existing non-CBD lines just to be trendy,” he advises. “CBD Living is a CBD company. Always has been, always will be. Expanding into the pet product sphere was a natural step for us.” For pets, the company offers a 5-milligram CBD supplement in a hard chew, a soft chew and a gel cap, covering a wide range of consumer needs.

There’s an education requirement for these products as well. The average customer may be interested in CBD products but not know what to look for. “Consumers need education on CBD, the industry and different products available,” explains Gillen. “Consumers should know what compliant packaging and labeling looks like, how to properly read it, and how to access full-panel third-party lab results via the QR code, which should clearly be visible on the label, to be reassured of the product’s safety, ingredients and potency.”

Further, price is always a huge factor for consumers. Remember that most of these CBD products will also be available on the manufacturers’ websites and other online sources. “Retailers should be confident that the product they are selling in their store will be less expensive in retail locations than on a manufacturer’s website,” notes Gillen. “Additionally, for those just starting in offering CBD pet products, keep it simple with a limited SKU selection.”

He adds: “As for merchandising techniques, retailers should place product in high-traffic areas and should utilize marketing resources from their vendor, including stickers, floor decals, window clings and educational material.”

Pandemic Price Slashing Means CBD Bargains For Seniors – Forbes

Online CBD sales are attractive to boomers


The Covid outbreak and its fallout on the cannabis and CBD markets are under intense scrutiny by industry observers. Commercial closures, rampant anxiety and focus on self-care are only some of the factors driving shifts in consumer behaviors. Particularly for the overcrowded CBD market, these changes have far-reaching implications.

With millions of jobless and the greatest recession in US history looming on the horizon, consumers are tightening their belts and looking for value in their self-care products. CBD companies are taking note and, with brick and mortar outlets shuttered, they are moving online with deals to attract the budget-conscious consumer. This spells good news for older adult CBD enthusiasts.

I emailed and spoke on the phone with Virginia Lee, CBD Research Manager at the Chicago-based Brightfield Group, about the CBD consumption patterns of Baby Boomers and elder adults, and how they are positioned to benefit from this new price-slashing trend.

Because boomers’ awareness of CBD’s health benefits is growing, Lee explained, many are shifting from trial use to becoming daily users. In fact, the number of boomers who reported using CBD 5 or more times per week rose from 36% in 2019 to over half (56%) in 2020, according to Brightfield Group’s consumer insights. They also found that 19% of boomer CBD consumers reported using CBD multiple times per day.

When questioned during the period from March 16-19, 27% of CBD-using boomers answered that they expected to use more CBD during the Covid-19 crisis.

 CBD During Covid

The CBD space was already glutted before the pandemic hit, but the coronavirus may do its own form of Darwinian winnowing. Writing about COVID’s effects on the CBD market in the Brightfield Group blog, Managing Director, Bethany Gomez, explains:

Smaller brands often rely on small or local retailers to distribute the bulk of their products. In the current environment, mass shuttering of retailers around the country is likely to deal a death blow to many of the smaller brands in the market. This could actually work in the favor of many of the larger brands, who are better positioned to weather the storm and be able to support a robust e-comm strategy. If they can keep the lights on over the next few months, they may be competing in a much less crowded field once we emerge from the crisis.” 

Part of that e-comm strategy is to offer budget-conscious consumers the CBD offers they are looking for. Boomers take note!

 Price Reductions and Free Shipping

Most of us aren’t used to seeing CBD products other than lip balms sold for under $10. But for a few days in May, Bluebird Botanicals offered 40% off its Classic CBD Oil (1/3 oz originally priced at $12.95) for $7.77.

To celebrate International Day of Families, CBDMEDIC is offering a buy-1-get-1-free product offer during May, along with a free hand sanitizer and free shipping in the US.

KoiCBD is also offering a limited-time-only buy-1-get-1-free with certain products.

Lee provides some insight from CBD industry leader Charlotte’s Web:

“Charlotte’s Web in its May 14, 2020 Q1 2020 earnings call stated that they had reduced their list prices across their portfolio by 15 to 20% in DTC (Direct-to-Consumer) and B2B in late March/April… Among the 7 topicals they launched in April, 3 are priced at $14.99.”

On the Charlotte’s Web website, signing up with your email will get you a 10% discount on your first order.

But the same email sign-up will get you a 15% discount at companies including Kanibi, PremiumJane, Rosebud, Medterra and PureKana.

Free 3-day shipping is another way companies including Lazarus Naturals and NuLeaf Naturals extend savings to customers.

For those running low on CBD, now’s a good time to let your fingers do the walking – and if you are a boomer, you’ll know what mean.

THC-Infused Semen Can Be A Side Effect Of Frequent Marijuana Use, Study Finds – Marijuana Moment

A scientist in a case that forced the release of a previously “secret” Justice Department document about federally authorized marijuana research this week is now calling on Congress to urge administrative action to more rapidly expand studies into the therapeutic potential of cannabis.

Sue Sisley of the Scottsdale Research Institute (SRI) and attorneys representing her facility say the Department of Justice is empowered to waive certain requirements and allow additional researchers to immediately grow their own cannabis for studies without registration under newly proposed regulations or even to obtain products from state-licensed dispensaries, for example.

They want lawmakers’ help pressuring the Trump administration to take advantage of a process they say would not necessarily violate international treaties that federal officials have long cited as a reason they’ve been slow to license new cultivators.

On Wednesday, the Justice Department’s Office of Legal Counsel (OLC) disclosed a memo that seemed to have been used by the Drug Enforcement Administration (DEA) to justify delaying approval of additional marijuana manufacturers for research purposes beyond the sole legal that scientists have had to rely on for half a century. That disclosure was the result of a Freedom of Information Act lawsuit filed by SRI last month.

Attorneys representing SRI said that the newly unveiled document helps explains what was happening behind closed doors for several years of inaction and delays after DEA initially said in 2016 that it would be approving more manufacturers.

But in their new letter to members of Congress, they identify a federal statute that they argue can be used by the attorney general to waive registration requirements, allowing research institutes to immediately grow their own cannabis for studies or to purchase it from licensed dispensaries instead of having to wait until new rigorous licensing rules go into effect.

“That Congress can fix these issues with legislation goes without saying. But what fewer recognize is that this Administration can cut through the regulatory red-tape right now,” Sisley and her lawyers wrote.

“DEA could, for example, exempt licensed Schedule I marijuana researchers from having to obtain a separate registration to manufacture marijuana, provided those researchers agree not to distribute any marijuana they manufacture. Alternatively, it could permit licensed Schedule I marijuana researchers to obtain marijuana from state-legal dispensaries. The executive’s authority to grant waivers under [federal code] is broad.”

SRI is one of dozens of applicants to become federally authorized cannabis cultivators for research purposes. It initially sued DEA three years after the agency said it would expand cultivation facilities, with SRI alleging an unlawful delay in approvals. That led the agency to announce in March that it is proposing new rules in order to process the applications.

Prior to the document’s release, it was unclear exactly what was holding DEA up from fulfilling their pledge. The OLC memo, written in 2018 but undisclosed to the public until this week, determined that DEA’s 2016 announcement about expansion would have violated international treaties—an analysis that the agency had declined to explain to applicants as their proposals languished for years.

OLC also found, however, that even the current system for marijuana research in the U.S.—which involves the National Institute on Drug Abuse contracting a single grow facility at the University of Mississippi to produce cannabis and DEA registering scientists who can obtain it—violates several provisions of international treaty obligations.

In particular, it determined that the existing process violates a provision stipulating that marijuana grown for research must be purchased and possessed by a single federal agency—a policy that DEA is seeking to adhere to under a recently revised rule change proposal released last month.

But SRI and its attorneys argue there’s a simpler solution, and that’s why they’re circulating a letter to members of Congress imploring action.

“In the United States, doing robust clinical research with marijuana should not be so difficult,” the letter from Sisley and her lawyers to members of the House and Senate says. “Scores of Americans rely on medical marijuana to treat a variety of symptoms, including our nation’s veterans and terminally ill. Not surprisingly, this issue has solid bipartisan support. It also has support among federal agencies including FDA, NIH, and DEA itself.”

While DEA’s new proposed rule change would seemingly address issues identified in the OLC memo—primarily by making it so DEA would be the sole agency in charge of possessing and purchasing cannabis for research—attorneys Shane Pennington and Matt Zorn said there’s a federal statute that would enable the Justice Department to circumvent the rulemaking process by unilaterally waiving registration requirements and setting its own regulations to abide by international treaties.

That code in question stipulates: “The Attorney General may, by regulation, waive the requirement for registration of certain manufacturers, distributors, or dispensers if he finds it consistent with the public health and safety.” Unlike other statutes concerning the issue, this one does not explicitly mention international treaty obligations.

“Plainly, given the undisputed urgency of the need for this research, waiving certain registration requirements to allow already-licensed Schedule I researchers obtain marijuana from real world or alternative sources would be ‘consistent with the public health and safety,’” the attorneys’ letter said.

Of course, the international treaties to which the U.S. is a party would still be in effect. But under the statute cited by SRI, the attorney general could theoretically impose any regulations that he felt were necessary to maintain compliance. For example, if the official were to make it so researchers could purchase marijuana from dispensaries, it could satisfy the requirement that research-grade cannabis be purchased and possessed by a single federal agency by allowing DEA to technically “own” the shop’s product.

“I should caution that it’s tough to answer these questions in the abstract because the answer in real life would depend on what the AG thought was necessary to comply with the OLC interpretation of the Single Convention,” Pennington said in an email to Marijuana Moment. He added that he is “not in any way conceding I agree with the OLC’s interpretation” but was simply speculating about how the federal government could allow researchers to immediately grow their own marijuana or study products from dispensaries while still complying with its analysis.

It was previously reported that the Justice Department, under then-Attorney General Jeff Sessions, a vociferous opponent of cannabis reform, blocked DEA from processing any of the several dozen cultivation license applications it received in response to the 2016 announcement. Attorney General William Barr views the issue differently, however, telling lawmakers that he’s pushed “very hard” to get more manufacturers approved and that he thinks “it’s very important to get those additional suppliers.”

The reason all of this matters to researchers and advocates is because of issues resulting from the monopolized cannabis supply for research purposes at the University of Mississippi. Studies have indicated that the marijuana it produces is not reflective of the cannabis sold in retail dispensaries in legal states, raising questions about the veracity of previous studies that have relied on it.

SRI, for its part, is hoping to become an approved marijuana manufacturer to supply studies into the potential therapeutic benefits of cannabis for post-traumatic stress disorder.

“Boiled down, the fact that a secret re-interpretation of an international treaty from 1961 has blocked the advancement of marijuana science in this country for the past three years is absurd,” the letter continues. “Allowing American scientists to cultivate or acquire marijuana grown in this country under strict DEA regulation and supervision is pro-science, pro-veteran, and pro-law enforcement. It puts America First and promotes public health and safety.”

Read SRI’s marijuana research letter to Congress below: 

SRI Marijuana Letter to Con… by Marijuana Moment on Scribd

Feds Sue Company Over Claims Its CBD Products Can Treat Cancer

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.